{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-100790","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2024-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.611679+00:00","generated_at":"2026-05-31T07:26:53.196882+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Renalytix gets Nasdaq extension to Oct 25, 2024; transfers to Capital Market","bullets":["Nasdaq Hearings Panel grants until October 25, 2024 to regain compliance with minimum bid price of $1.00.","ADSs transfer from Nasdaq Global Market to Nasdaq Capital Market effective August 27, 2024.","Must also achieve $2.5M minimum stockholders' equity and provide 12-month income projections.","Unaudited cash position $4.7M as of June 30, 2024; cash runway into Q4 2024.","Advanced discussions with stakeholders for funding and refreshed business plan."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-100790","json":"https://secwatch.observer/filing/0000950170-24-100790.json","markdown":"https://secwatch.observer/filing/0000950170-24-100790.md","text":"https://secwatch.observer/filing/0000950170-24-100790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024100790/0000950170-24-100790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024100790/rnlx-20240823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:26:53.196882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}